Effect of prolyl endopeptidase on digestive-resistant gliadin peptides in vivo

被引:87
作者
Piper, JL
Gray, GM
Khosla, C
机构
[1] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Med, Stanford, CA 94305 USA
关键词
D O I
10.1124/jpet.104.068429
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many gluten peptides elicit proliferative responses from T cells from Celiac Sprue patients, influencing the pathogenesis of this small intestinal disorder. These peptides are Pro- and Gln-rich in character, suggesting that resistance to proteolysis promotes their toxicity. To test this hypothesis, we analyzed the digestive resistance of a panel of alpha- and gamma-gliadin peptides believed to induce toxicity via diverse mechanisms. Most were highly resistant to gastric and pancreatic protease digestion, but they were digested by intestinal brush-border peptidases. In some instances, there was accumulation of relatively long intermediates. Control peptides from gliadin and myoglobin revealed that digestive resistance depended on factors other than size. Prolyl endopeptidase (PEP) supplementation substantially reduced the concentrations of these peptides. To estimate a pharmacologically useful PEP dose, recombinant PEP was coperfused into rat intestine with the highly digestive-resistant 33-mer peptide LQLQPF(PQPQLPY)(3)PQPQPF(PEP:peptide weight ratio 1: 50 to 1: 5). PEP dosing experiments indicate significant changes in the average residence time. The in vivo benefit of PEP was verified by coperfusion with a mixture of 33-mer and partially proteolyzed gliadin. These data verify and extend our earlier proposal that gliadin peptides, although resistant to proteolysis, can be processed efficiently by PEP supplementation. Indeed, PEP may be able to treat Celiac Sprue by reducing or eliminating such peptides from the intestine.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 27 条
[1]  
AHNEN DJ, 1982, J BIOL CHEM, V257, P2129
[2]   The intestinal T cell response to α-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase [J].
Arentz-Hansen, H ;
Körner, R ;
Molberg, O ;
Quarsten, H ;
Vader, W ;
Kooy, YMC ;
Lundin, KEA ;
Koning, F ;
Roepstorff, P ;
Sollid, LM ;
McAdam, SN .
JOURNAL OF EXPERIMENTAL MEDICINE, 2000, 191 (04) :603-612
[3]   IN-VITRO MUCOSAL DIGESTION OF SYNTHETIC GLIADIN-DERIVED PEPTIDES IN CELIAC-DISEASE [J].
CORNELL, HJ ;
RIVETT, DE .
JOURNAL OF PROTEIN CHEMISTRY, 1995, 14 (05) :335-339
[4]   Partial in vitro digestion of active gliadin-related peptides in celiac disease [J].
Cornell, HJ .
JOURNAL OF PROTEIN CHEMISTRY, 1998, 17 (08) :739-744
[5]  
DEEM RL, 1991, CLIN EXP IMMUNOL, V83, P79
[6]   INVITRO (ORGAN-CULTURE) STUDIES OF THE TOXICITY OF SPECIFIC A-GLIADIN PEPTIDES IN CELIAC-DISEASE [J].
DERITIS, G ;
AURICCHIO, S ;
JONES, HW ;
LEW, EJL ;
BERNARDIN, JE ;
KASARDA, DD .
GASTROENTEROLOGY, 1988, 94 (01) :41-49
[7]   ORIGIN OF REGIONAL AND SPECIES-DIFFERENCES IN INTESTINAL GLUCOSE-UPTAKE [J].
FERRARIS, RP ;
LEE, PP ;
DIAMOND, JM .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 257 (05) :G689-G697
[8]  
FISHER RB, 1950, J ANAT, V84, P272
[9]  
Ganong W.F., 1979, Review of medical physiology, Vninth
[10]   Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation [J].
Halttunen, T ;
Mäki, M .
GASTROENTEROLOGY, 1999, 116 (03) :566-572